IFF Secures First Heart Health Claim for Soy Protein in Australia and New Zealand
Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Very Positive)
Tags
Key Terms
isolated soy proteinmedical
Isolated soy protein is a highly refined powder made from soybeans that contains mostly protein and little carbohydrate or fat, used to boost protein content, improve texture, or extend shelf life in processed foods and supplements. Investors care because it is a widely traded ingredient whose price, supply, labeling rules (including allergen disclosure), and role in plant-based products can affect food manufacturers’ costs, margins, and market positioning.
cardiovascular healthmedical
Cardiovascular health is the overall condition and functioning of the heart and blood vessels that circulate blood, including measures like blood pressure, cholesterol and blood flow. It matters to investors because demand for drugs, devices, tests and preventive services that affect heart and vessel health creates revenue opportunities and regulatory and clinical risks for companies; think of it like the engine and fuel system of a car, where how well it runs drives demand for repairs, upgrades and ongoing maintenance.
dyslipidemiamedical
Dyslipidemia is a medical condition where the levels of fats in the blood—such as cholesterol and triglycerides—are outside the healthy range, increasing the risk of artery blockages and heart disease; think of it as having oily buildup in plumbing that can slow or clog flow. It matters to investors because it drives demand for drugs, medical devices and diagnostics, influences healthcare costs and insurance payouts, and can affect the commercial and regulatory prospects of companies developing treatments.
blood lipidsmedical
Blood lipids are fats and fat-like substances that travel in the bloodstream—most commonly cholesterol and triglycerides—and act like fuel and building blocks for the body. For investors, lipid levels matter because they drive demand for medical tests, drugs and devices, influence long-term healthcare costs and patient outcomes, and can shape regulatory and insurance decisions; think of them as the oil level that keeps a machine running or signals when maintenance or new parts are needed.
Food Standards Australia New Zealand (FSANZ)regulatory
Food Standards Australia New Zealand (FSANZ) is the joint government agency that sets and enforces food safety and labeling rules, evaluates additives and novel ingredients, and issues approvals for foods sold in Australia and New Zealand. For investors, FSANZ decisions act like traffic signals for the food sector: they determine which products can enter the market, what labeling and safety steps companies must follow, and therefore influence costs, sales potential and regulatory risk.
Regulatory milestone opens heart health growth opportunities for food and beverage manufacturers
ST. LOUIS--(BUSINESS WIRE)--
IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients and health & biosciences announced today that a new heart health claim for isolated soy protein has been accepted by the Food Standards Australia New Zealand (FSANZ). The approval enables food and beverage manufacturers in Australia and New Zealand to link soy protein consumption with healthy blood cholesterol levels.
First heart health claim approved for soy protein in Australia and New Zealand.
“For decades, IFF has invested in the science behind soy protein and its role in supporting cardiovascular health,” said Tony Andrew, vice president of protein solutions for IFF Food Ingredients. “This approved claim validates years of rigorous research and collaboration. With our deep expertise in ingredient science, application and scale, we are well-positioned to help our customers translate this milestone into differentiated products that deliver on health, taste and sustainability.”
The claim is supported by a multi-year, cross-continental research collaboration backed by IFF, the Soy Nutrition Institute Global and the U.S. Soybean Export Council, involving researchers from Australia and the University of Toronto. Under the new permission, foods formulated to help consumers achieve a daily intake of 20-25 grams of isolated soy protein, consumed as part of a healthy, balanced diet, may carry the heart health claim.
Isolated soy protein is a 90% plant-based, high-quality, complete protein containing all nine essential amino acids. Its functional versatility makes it widely used in beverages, dairy alternatives, nutrition bars, snacks and plant-based foods — categories where consumers increasingly seek products that combine taste with clinically supported health benefits. This approval marks a significant milestone for plant-based nutrition, offering brands new opportunities to develop products positioned to support heart health.
“The clinical evidence supports a causal relationship between isolated soy protein consumption and improved blood lipids,” said Dr. Alan Barclay, Ph.D., lead author of the FSANZ submission. “With dyslipidemia affecting around 60 percent of Australian adults1 and many New Zealanders, daily consumption of soy protein offers a practical food-based nutrition strategy to help manage cholesterol and reduce cardiovascular risk.”
Australia and New Zealand join 11 other countries, including the United States, Canada and Japan, that recognize the link between soy protein consumption and heart health. Backed by decades of research and innovation on the SOLAE® SUPRO® soy protein portfolio, IFF is working with food and beverage manufacturers across the region to develop next-generation products that combine nutrition science, functionality and consumer appeal.
Welcome to IFF
At IFF (NYSE: IFF), we make joy through science, creativity and heart. As the global leader in taste, scent, food ingredients, health and biosciences, we’re innovating for the future. Every day, we deliver groundbreaking, sustainable solutions that elevate products people love — advancing wellness, delighting the senses and enhancing the human experience.Learn more at iff.com, LinkedIn, Instagram and Facebook.
